Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JAB-30355 (Jacobio Pharma)
- Development stage
- Phase 2
- Lead developer
- Jacobio Pharmaceuticals Co., Ltd.
01
Overview
JAB-30355 (Jacobio Pharma): sourced facts only. name: "Overall, the in vitro data demonstrated that JAB-30355 is a potent and selective p53-Y220C reactivator." [DOI:10.1158/1538-7445.am2024-5940]; target: "Overall, the in vitro data demonstrated that JAB-30355 is a potent and selective p53-Y220C reactivator." [DOI:10.1158/1538-7445.am2024-5940]; developer: "1Jacobio Pharmaceuticals Co., Ltd, BeiJing, China." [DOI:10.1158/1538-7445.am2024-5940]; stage: "Furthermore, JAB-30355 exhibited dose-dependent anti-tumor activity, inducing tumor stasis or regression in multiple CDX and PDX models of ovarian cancer, pancreatic cancer, gastric cancer, and small cell lung cancer, with overall good tolerability." [DOI:10.1158/1538-7445.am2024-5940]
02
Targets
TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on JAB-30355 (Jacobio Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JAB-30355 (Jacobio Pharma).